{"id":555,"date":"2026-02-27T14:09:20","date_gmt":"2026-02-27T12:09:20","guid":{"rendered":"http:\/\/example.test\/?page_id=555"},"modified":"2026-03-25T11:06:52","modified_gmt":"2026-03-25T09:06:52","slug":"glp-1-vs-gip-vs-glucagon-receptors","status":"publish","type":"page","link":"https:\/\/life-peptide.com\/cs\/glp-1-vs-gip-vs-glucagon-receptors\/","title":{"rendered":"Receptory GLP-1 vs GIP vs glukagonu"},"content":{"rendered":"<h1 class=\"wp-block-heading has-text-align-center\">Receptory GLP-1 vs GIP vs glukagonu<\/h1>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-center\"><strong><strong>Struktur\u00e1ln\u00ed architektura a rozd\u00edly v n\u00e1sledn\u00e9 signalizaci ve v\u00fdzkumu metabolismu<\/strong><\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Receptory pro GLP-1, GIP a glukagon pat\u0159\u00ed do rodiny receptory sp\u0159a\u017een\u00fdmi s G-proteinem (GPCR) t\u0159\u00eddy B a hraj\u00ed kl\u00ed\u010dovou roli v metabolick\u00e9 signalizaci. A\u010dkoliv jsou struktur\u00e1ln\u011b p\u0159\u00edbuzn\u00e9, tyto receptory se v\u00fdrazn\u011b li\u0161\u00ed v tk\u00e1\u0148ov\u00e9 distribuci, vnitrobun\u011b\u010dn\u00e9 signaliza\u010dn\u00ed preferenci a fyziologick\u00e9 funkci.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pochopen\u00ed rozd\u00edl\u016f na \u00farovni receptor\u016f je z\u00e1sadn\u00ed p\u0159i porovn\u00e1v\u00e1n\u00ed:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Agonist\u00e9 GLP-1 receptor\u016f (nap\u0159. semaglutid)<\/li>\n\n\n\n<li>Du\u00e1ln\u00ed agonist\u00e9 GLP-1\/GIP (nap\u0159. tirzepatid)<\/li>\n\n\n\n<li>Trojit\u00e1 agonisty GLP-1\/GIP\/glukagonu (nap\u0159. retatrutid)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">\u0160ir\u0161\u00ed p\u0159ehled t\u011bchto slou\u010denin naleznete v na\u0161em <a href=\"\/cs\/glp-1-metabolic-research-guide\/\" data-type=\"page\" data-id=\"529\">Pr\u016fvodce v\u00fdzkumem metabolismu GLP-1<\/a>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>1. GLP-1 receptor (GLP1R)<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>T\u0159\u00edda receptoru<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">GPCR t\u0159\u00eddy B (rodina sekretinu)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Distribuce v tk\u00e1n\u00edch<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Pankreatick\u00e9 beta bu\u0148ky<\/li>\n\n\n\n<li>Gastrointestin\u00e1ln\u00ed trakt<\/li>\n\n\n\n<li>Moanov\u00fd kmen a hypothalamus<\/li>\n\n\n\n<li>Kardiovaskul\u00e1rn\u00ed tk\u00e1\u0148<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Aktivace GLP-1 receptoru prim\u00e1rn\u011b stimuluje vazbu na Gs protein, \u010d\u00edm\u017e zvy\u0161uje intracelul\u00e1rn\u00ed cAMP a aktivuje proteinkin\u00e1zu A (PKA), co\u017e zesiluje na gluk\u00f3ze z\u00e1vislou sekreci inzulinu (Drucker, 2018; Nauck &amp; Meier, 2019).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sekund\u00e1rn\u00ed sign\u00e1ln\u00ed dr\u00e1hy zahrnuj\u00ed aktivaci PI3K\/Akt a ERK, co\u017e p\u0159isp\u00edv\u00e1 k p\u0159e\u017e\u00edv\u00e1n\u00ed beta-bun\u011bk a modulaci chuti k j\u00eddlu prost\u0159ednictv\u00edm drah centr\u00e1ln\u00ed nervov\u00e9 soustavy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"\/cs\/product\/semaglutide-10-mg\/\" data-type=\"product\" data-id=\"303\">Semaglutid <\/a>p\u016fsob\u00ed jako selektivn\u00ed agonista receptoru GLP-1 a zaji\u0161\u0165uje c\u00edlenou aktivaci t\u00e9to inkretinov\u00e9 dr\u00e1hy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>2. GIP receptor (GIPR)<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>T\u0159\u00edda receptoru<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">GPCR t\u0159\u00eddy B<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Distribuce v tk\u00e1n\u00edch<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Pankreatick\u00e9 beta bu\u0148ky<\/li>\n\n\n\n<li>Tukov\u00e1 tk\u00e1\u0148<\/li>\n\n\n\n<li>Oblasti centr\u00e1ln\u00edho nervov\u00e9ho syst\u00e9mu<\/li>\n\n\n\n<li>Gastrointestin\u00e1ln\u00ed trakt<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Podobn\u011b jako GLP-1R se GIPR prim\u00e1rn\u011b v\u00e1\u017ee na Gs proteiny a zvy\u0161uje intracelul\u00e1rn\u00ed cAMP. Sign\u00e1ln\u00ed dr\u00e1ha GIP v\u0161ak ovliv\u0148uje tak\u00e9 ukl\u00e1d\u00e1n\u00ed tuk\u016f v adipocytech, insulinotropn\u00ed amplifikaci a dr\u00e1hy distribuce \u017eivin (Campbell &amp; Drucker, 2013).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Zat\u00edmco po\u010d\u00e1te\u010dn\u00ed metabolick\u00e9 modely zpochyb\u0148ovaly \u00falohu GIP za ur\u010dit\u00fdch stav\u016f inzul\u00ednov\u00e9 rezistence, du\u00e1ln\u00ed agonismus receptor\u016f pro GLP-1\/GIP prok\u00e1zal ve srovn\u00e1n\u00ed se samotn\u00fdm GLP-1 \u200azlep\u0161en\u00e9 metabolick\u00e9 \u00fa\u010dinky (Frias et al., 2021; Jastreboff et al., 2022).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"\/cs\/product\/tirzepatide-10-mg\/\" data-type=\"product\" data-id=\"309\">Tirzepatid <\/a>vyu\u017e\u00edv\u00e1 tento mechanismus du\u00e1ln\u00edho receptoru k roz\u0161\u00ed\u0159en\u00ed modulace inkretinov\u00e9 dr\u00e1hy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>3. Glukagonov\u00fd receptor (GCGR)<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>T\u0159\u00edda receptoru<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">GPCR t\u0159\u00eddy B<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Distribuce v tk\u00e1n\u00edch<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>J\u00e1tra (hepatocyty)<\/li>\n\n\n\n<li>Ledvina<\/li>\n\n\n\n<li>Tukov\u00e1 tk\u00e1\u0148<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Aktivace glukagonov\u00e9ho receptoru stimuluje tvorbu gluk\u00f3zy v j\u00e1trech a oxidaci lipid\u016f prost\u0159ednictv\u00edm signalizace cAMP zprost\u0159edkovan\u00e9 proteiny Gs (Habegger et al., 2010). Ovliv\u0148uje tak\u00e9 dr\u00e1hy v\u00fddeje energie a syst\u00e9movou metabolickou regulaci.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Na rozd\u00edl od GLP-1R a GIPR, kter\u00e9 prim\u00e1rn\u011b moduluj\u00ed insulinotropn\u00ed dr\u00e1hy, m\u00e1 aktivace receptoru pro glukagon dominantn\u00ed jatern\u00ed metabolick\u00fd \u00fa\u010dinek.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"\/cs\/product\/retatrutide-10-mg\/\" data-type=\"product\" data-id=\"331\">Retatrutid <\/a>zahrnuje aktivaci glukagonov\u00e9ho receptoru krom\u011b signalizace receptor\u016f pro GLP-1 a GIP, co\u017e zav\u00e1d\u00ed \u0161ir\u0161\u00ed syst\u00e9movou metabolickou komplexitu (Jastreboff et al., 2023).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>4. Strukturn\u00ed a funk\u010dn\u00ed srovn\u00e1n\u00ed<\/strong><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Funkce<\/strong><\/td><td><strong>GLP-1R<\/strong><\/td><td><strong>GIPR<\/strong><\/td><td><strong>GCGR<\/strong><\/td><\/tr><\/thead><tbody><tr><td><strong>Rod receptor\u016f<\/strong><\/td><td>GPCR t\u0159\u00eddy B<\/td><td>GPCR t\u0159\u00eddy B<\/td><td>GPCR t\u0159\u00eddy B<\/td><\/tr><tr><td><strong>Hlavn\u00ed zam\u011b\u0159en\u00ed na tk\u00e1\u0148<\/strong><\/td><td>Slinivka b\u0159i\u0161n\u00ed + CNS<\/td><td>Slinivka + tukov\u00e1 tk\u00e1\u0148<\/td><td>J\u00e1tra<\/td><\/tr><tr><td><strong>Dominantn\u00ed sign\u00e1l<\/strong><\/td><td>cAMP\/PKA<\/td><td>cAMP + metabolick\u00e1 modulace<\/td><td>cAMP + jatern\u00ed energetick\u00e9 dr\u00e1hy<\/td><\/tr><tr><td><strong>Hlavn\u00ed role ve v\u00fdzkumu<\/strong><\/td><td>Inkretinov\u00e1 inzulinov\u00e1 signalizace<\/td><td>Inkretinov\u00e1 synergie<\/td><td>Energerick\u00fd v\u00fddej a jatern\u00ed metabolismus<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">A\u010dkoli v\u0161echny t\u0159i receptory aktivuj\u00ed sign\u00e1ln\u00ed kask\u00e1dy cAMP, rozd\u00edly v distribuci v tk\u00e1n\u00edch a receptorov\u00e1 preference vytv\u00e1\u0159ej\u00ed z\u00e1sadn\u011b odli\u0161n\u00e9 metabolick\u00e9 v\u00fdstupy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>5. Synergie v\u00edce receptor\u016f u du\u00e1ln\u00edch a triplicitn\u00edch agonist\u016f<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Aktivace jedin\u00e9ho receptoru (pouze GLP-1) vyvol\u00e1v\u00e1 c\u00edlen\u00e9 inkretinov\u00e9 \u00fa\u010dinky. Du\u00e1ln\u00ed aktivace (GLP-1 + GIP) zesiluje insulinotropn\u00ed sign\u00e1ln\u00ed dr\u00e1hu a m\u016f\u017ee modifikovat metabolickou odpov\u011b\u010f adipocyt\u016f (Frias et al., 2021).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Aktivace trojit\u00e9ho receptoru p\u0159id\u00e1v\u00e1 jatern\u00ed signalizaci zprost\u0159edkovanou glukagonem, \u010d\u00edm\u017e ovliv\u0148uje oxidaci lipid\u016f a celkov\u00fd energetick\u00fd v\u00fddej (Jastreboff et al., 2023).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Toto vrstven\u00ed na \u00farovni receptor\u016f vysv\u011btluje, pro\u010d:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Semaglutid p\u0159edstavuje selektivn\u00ed inkretinov\u00fd model<\/li>\n\n\n\n<li>Tirzepatid roz\u0161i\u0159uje inkretinovou synergii<\/li>\n\n\n\n<li>Retatrutid zav\u00e1d\u00ed syst\u00e9movou metabolickou modulaci<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Zvy\u0161ov\u00e1n\u00ed po\u010dtu c\u00edlov\u00fdch receptor\u016f zvy\u0161uje slo\u017eitost n\u00e1sledn\u00e9 signalizace a n\u00e1roky na experiment\u00e1ln\u00ed modelov\u00e1n\u00ed.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>6. CNS vs perifern\u00ed distribuce<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Receptory GLP-1 jsou siln\u011b exprimov\u00e1ny v oblastech hypothalamu a mozkov\u00e9ho kmene spojen\u00fdch s regulac\u00ed chuti k j\u00eddlu (Drucker, 2018). Receptory GIP jsou rovn\u011b\u017e p\u0159\u00edtomny v tk\u00e1n\u00edch CNS, a\u010dkoli jejich centr\u00e1ln\u00ed role je st\u00e1le p\u0159edm\u011btem aktivn\u00edho zkoum\u00e1n\u00ed.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Glukagonov\u00e9 receptory jsou p\u0159eva\u017en\u011b jatern\u00ed, co\u017e zd\u016fraz\u0148uje sp\u00ed\u0161e perifern\u00ed metabolickou kontrolu ne\u017e centr\u00e1ln\u00ed regulaci chuti k j\u00eddlu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tyto distribu\u010dn\u00ed rozd\u00edly p\u0159isp\u00edvaj\u00ed k odli\u0161n\u00fdm mechanistick\u00fdm v\u00fdsledk\u016fm v komparativn\u00edm v\u00fdzkumu receptor\u016f.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>7. \u00davahy o experiment\u00e1ln\u00edm designu<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">P\u0159i n\u00e1vrhu model\u016f pro metabolick\u00fd v\u00fdzkum:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Selektivn\u00ed agoniste GLP-1 umo\u017e\u0148uj\u00ed kontrolovan\u00e9 hodnocen\u00ed inkretinov\u00e9 dr\u00e1hy<\/li>\n\n\n\n<li>Du\u00e1ln\u00ed agonist\u00e9 vy\u017eaduj\u00ed modelov\u00e1n\u00ed vz\u00e1jemn\u00e9ho p\u016fsoben\u00ed sign\u00e1ln\u00edch drah v pankreatu a v tukov\u00e9 tk\u00e1ni<\/li>\n\n\n\n<li>Trojit\u00ed agonist\u00e9 vy\u017eaduj\u00ed sledov\u00e1n\u00ed jatern\u00edho metabolizmu<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">P\u0159i interpretaci experiment\u00e1ln\u00edch dat je nutn\u00e9 vz\u00e1jemnost receptor\u016f (cross-talk) a kompenza\u010dn\u00ed endokrinn\u00ed odpov\u011bdi vz\u00edt v \u00favahu.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>8. \u010casto kladen\u00e9 ot\u00e1zky<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Jsou receptory pro GLP-1, GIP a glukagon struktur\u00e1ln\u011b p\u0159\u00edbuzn\u00e9?<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ano. V\u0161echny pat\u0159\u00ed do rodiny GPCR t\u0159\u00eddy B, ale li\u0161\u00ed se ligandovou specifitou a tk\u00e1\u0148ovou expres\u00ed.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Pro\u010d aktivace GIP receptoru m\u011bn\u00ed v\u00fdsledky?<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Signalizace GIP receptoru ovliv\u0148uje adipocytov\u00e9 a insulinotropn\u00ed dr\u00e1hy a zesiluje inkretinov\u00e9 \u00fa\u010dinky.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Pro\u010d zahrnout aktivaci glukagonov\u00e9ho receptoru?<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Signalizace glukagonov\u00e9ho receptoru ovliv\u0148uje jatern\u00ed metabolismus a syst\u00e9mov\u00fd energetick\u00fd v\u00fddej, co\u017e roz\u0161i\u0159uje rozsah metabolick\u00e9ho modelov\u00e1n\u00ed.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>9. V\u011bdeck\u00e9 odkazy<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Drucker DJ. Mechanizmy \u00fa\u010dinku a terapeutick\u00e9 pou\u017eit\u00ed glukagonu podobn\u00e9ho peptidu-1. <em>Bun\u011b\u010dn\u00fd metabolismus<\/em>. 2018.<br>Nauck MA, Meier JJ. Incretinov\u00e9 hormony: Jejich \u00faloha ve zdrav\u00ed a nemoci. <em>Diabetes, obezita a metabolismus<\/em>. 2019.<br>Campbell JE, Drucker DJ. Farmakologie, fyziologie a mechanismy p\u016fsoben\u00ed inkretinov\u00fdch hormon\u016f. <em>Bun\u011b\u010dn\u00fd metabolismus<\/em>. 2013.<br>Habegger KM et al. Metabolick\u00e9 \u00fa\u010dinky glukagonu znovu zkoum\u00e1ny. <em>Nature Reviews Endocrinology<\/em>. 2010.<br>Frias JP a kol. Tirzepatid versus semaglutid jednou t\u00fddn\u011b u diabetu 2. typu. <em>New England Journal of Medicine<\/em>. 2021.<br>Jastreboff AM et al. Tirzepatid jednou t\u00fddn\u011b k l\u00e9\u010db\u011b obezity. <em>NEJM<\/em>. 2022.<br>Jastreboff AM et al. Trojn\u00fd hormon\u00e1ln\u00ed receptorov\u00fd agonista retatrutid p\u0159i obezit\u011b. <em>NEJM<\/em>. 2023.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>10. Souvisej\u00edc\u00ed metabolick\u00e9 v\u00fdzkumn\u00e9 slou\u010deniny<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/cs\/product\/semaglutide-10-mg\/\" data-type=\"product\" data-id=\"309\">Semaglutid <\/a>(agonista GLP-1 receptor\u016f)<\/li>\n\n\n\n<li><a href=\"\/cs\/product\/tirzepatide-10-mg\/\" data-type=\"product\" data-id=\"309\">Tirzepatid <\/a>(du\u00e1ln\u00ed agonista GLP-1\/GIP)<\/li>\n\n\n\n<li><a href=\"\/cs\/product\/retatrutide-10-mg\/\" data-type=\"product\" data-id=\"331\">Retatrutid <\/a>(trojn\u00e1sobn\u00fd agonista GLP-1\/GIP\/glukagonu)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Proch\u00e1zet v\u0161echny slou\u010deniny na b\u00e1zi inkretinu v <a href=\"\/cs\/category\/metabolic-research-peptides\/\">Kategorie metabolick\u00e9ho v\u00fdzkumu.<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>GLP-1 vs GIP vs glucagon receptors Structural architecture &amp; downstream signaling differences in metabolic research GLP-1, GIP, and glucagon receptors belong to the class B G protein\u2013coupled receptor (GPCR) family and play central roles in metabolic signaling. Although structurally related, these receptors differ significantly in tissue distribution, intracellular signaling bias, and physiological function. Understanding receptor-level [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-555","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/pages\/555","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/comments?post=555"}],"version-history":[{"count":4,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/pages\/555\/revisions"}],"predecessor-version":[{"id":613,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/pages\/555\/revisions\/613"}],"wp:attachment":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/media?parent=555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}